Abstract Details

Title Evaluation of Headache Profiles in Pediatric Patients Pre and Post Participation in Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody (Anti-CGRP mAb) Studies

Topic Headache

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 15-003

Objective Examine headache severity and frequency in pediatric patients pre and post migraine prevention studies treating with Anti-CGRP mAbs.

Background The use of Anti-CGRP mAbs for the prophylaxis treatment of migraine has been shown to improve quality of life and decrease migraine frequency and severity in adult patients. This treatment is being examined with pediatric patients. The goal of this study was to assess headache characteristics in patients enrolled in Anti-CGRP mAb studies at three time points (pre-study, post-study, and 6-12 month post-study).

Design/Methods Retrospective chart review 14 patients (10-17 years-old) treated with Erenumab (n=10) or Galcanezumab (n=5) (One switched Galcanezumab to Erenumab). Evaluated number of monthly headache days, headache severity, and HIT-6 score at three time points. Recorded oral medication use pre and post-study and assessed side effects.

Results Post study 7/14 patients remained on Anti-CGRP mAbs, several discontinued due to age. Overall decreased HIT-6 scores at post-study times 1 and 2. Scores: pre-study χ¯=66.23(61–78), post-study 1 χ¯=63.92(57-78), and post-study 2 χ¯=62.45(48–78). HIT-6 score reduction post-study 1 χ¯=-2.82(-9-1) and post-study 2 χ¯=-4.73(-22–1). One patient had an increase in HIT-6 score. Number monthly headache days; pre-study=22.71(8-30), post-study 1 χ¯=18.14(2-30), and post-study 2 χ¯=14(1-30). Headache severity within subject post-time 1 χ¯=-1.58(-5-1) and post-time 2 χ¯=-1.95 (-6-1). One patient reported “intolerance” to the medication. Three patients experienced incidental traumatic brain injury on the medication. On average, patients were able to discontinue 1.43 preventative migraine medications and 1.62 rescue medications while on Anti-CGRP mAb.

Conclusions Anti-CGRP mAbs were effective in decreasing headache frequency and severity in some patients. There were no severe treatment side effects. Overall, the number of oral medications were reduced.

Authors/Disclosures
PRESENTER	No disclosure on file
Jennifer W. McVige, MD, FAAN (Dent Neurological Institute)	Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theranica. Dr. McVige has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/AbbVie. Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. Dr. McVige has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly. Dr. McVige has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. McVige has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurelis. The institution of Dr. McVige has received research support from Amgen. The institution of Dr. McVige has received research support from Eli Lily. The institution of Dr. McVige has received research support from Biohaven. The institution of Dr. McVige has received research support from Lundbeck. The institution of Dr. McVige has received research support from Dent Family Foundation. Dr. McVige has a non-compensated relationship as a Neurology Board with UCNS that is relevant to AAN interests or activities. Dr. McVige has a non-compensated relationship as a Board Exam Board Member with ABPN that is relevant to AAN interests or activities.
Patrick Eugeni (1998)	Mr. Eugeni has nothing to disclose.

��ɫ��

��ɫ��